Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03551951). This is a study registration, not published results. Lead sponsor: University of Missouri-Columbia. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 320 participants (ESTIMATED). Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer. Interventions: DIAGNOSTIC_TEST: Test for circulating tumor cells, DNA alterations. Primary outcome measures: Number of CTC/DTC in blood , At baseline; Number of CTC/DTC in urine , At baseline; Number of CTC/DTC in bone marrow , At baseline; Quantity of cfDNA in blood , At baseline; Quantity of cfDNA in urine , At baseline; Quantity of cfDNA in bone marrow , At baseline. Brief summary: Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies and improve screening.